Peptide record

TPDB26157

Antibacterial Anticancer Toxicity standard
14 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB26157
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia
standard
No
A 14-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Sequence
VKRFKLFFRKLKSV
Physicochemical Analysis
C88H146N24O16
ANDCEQGHIMPTWY
K
1796.28
12.44
6
0
7
+6
1.34
-0.071
97.14
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
0
A
2
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
2
L
4
K
0
M
3
F
0
P
1
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 2 K: 4 M: 0 F: 3 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
14
C88H146N24O16
1796.28
12.44
+6
1.34
-0.071
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
Toxicity
72.37±2.7 µM
Cytotoxic
IC50 | 72.37±2.7 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Pro-apoptotic cationic host defense peptides rich in lysine or arginine to reverse drug resistance by disrupting tumor cell membrane. | Amino Acids | 2017
Evidence 2 Activity

Activity

<20% Hemolysis
Toxicity
120 µM
Hemolytic Cytotoxic
<20% Hemolysis | 120 | µM | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Pro-apoptotic cationic host defense peptides rich in lysine or arginine to reverse drug resistance by disrupting tumor cell membrane. | Amino Acids | 2017
Evidence 3 Activity

Activity

IC50
Toxicity
72.37
Hemolytic Cytotoxic
Hemolytic_activity: Rabbit red blood cells: modest hemolytic activity(as show in Fig.2) | Cytotoxicity: HUVEC: IC50=72.37±2.7 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Amino Acids. 2017 Sep 49(9):1601-1610.